Neil Cashman on Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers
COMMENT Linse et al. have published an excellent and elegant biophysical study characterizing the targets and therapeutic mechanisms of four clinical Aβ antibodies. The results provide yet more evidence that disease-modifying activity in AD requires targeting of ...